journal article·2020-12-23

Macrophage-Membrane-Camouflaged Disintegrable and Excretable Nanoconstruct for Deep Tumor Penetration

Kishwor Poudel, Asmita Banstola, Milan Gautam, Zarchi Soe, Cao Dai Phung, Le Minh Pham, Jee-Heon Jeong, Han-Gon Choi, Sae Kwang Ku, Tuan Hiep Tran, Chul Soon Yong, Jong Oh Kim

ACS Applied Materials & Interfaces· Volume 12· Issue 51
Publisher page

Abstract

The consolidation of nanovectors with biological membranes has recently been a subject of interest owing to the prolonged systemic circulation time and delayed clearance by the reticuloendothelial system of such systems. Among the different biomembranes, the macrophage membrane has a similar systemic circulation time, with an additional chemotactic aptitude, targeting integrin proteins. In this study, we aimed to establish a laser-activated, disintegrable, and deeply tumor-penetrative nanoplatform. We used a highly tumor-ablative and laser-responsive disintegrable copper sulfide nanoparticle, loaded it with paclitaxel, and camouflaged it with the macrophage membrane for the fabrication of PTX@CuS@MMNPs. The in vitro paclitaxel release profile was favorable for release in the tumor microenvironment, and the release was accelerated after laser exposure. Cellular internalization was improved by membrane encapsulation. Cellular uptake, cytotoxicity, reactive oxygen species generation, and apoptosis induction of PTX@CuS@MMNPs were further improved upon laser exposure, and boosted permeation was achieved by co-administration of the tumor-penetrating peptide iRGD. In vivo tumor accumulation, tumor inhibition rate, and apoptotic marker expression induced by PTX@CuS@MMNPs were significantly improved by laser irradiation and iRGD co-administration. PTX@CuS@MMNPs induced downregulation of cellular proliferation and angiogenic markers but no significant changes in body weight, survival, or significant toxicities in vital organs after laser exposure, suggesting their biocompatibility. The disintegrability of the nanosystem, accredited to biodegradability, favored efficient elimination from the body. In conclusion, PTX@CuS@MMNPs showed promising traits in combination therapies for excellent tumor eradication.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea

College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea

College of Pharmacy, Hanyang University, 55, Hanyangdaehak-ro, Sangnok-gu, Ansan 426-791, Republic of Korea

Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Republic of Korea

Faculty of Pharmacy, Phenikaa University, Yen Nghia, Ha Dong District, Hanoi 100803, Vietnam

PHENIKAA Research and Technology Institute (PRATI), A&A Green Phoenix Group JSC, No. 167 Hoang Ngan, Cau Giay, Hanoi 11313, Vietnam

Funding

National Research Foundation of Korea

References (69)

Show source-provided references
1. 10.1021/acsnano.6b0665510.1021/acsnano.6b06655 ↗
2. 10.3389/fbioe.2019.0041510.3389/fbioe.2019.00415 ↗
3. 10.1038/nbt.333010.1038/nbt.3330 ↗
4. 10.1021/acsami.8b0664210.1021/acsami.8b06642 ↗
5. 10.1016/j.colsurfb.2018.05.05110.1016/j.colsurfb.2018.05.051 ↗
6. 10.1016/j.nantod.2015.10.00110.1016/j.nantod.2015.10.001 ↗
7. 10.1016/j.jconrel.2014.05.00610.1016/j.jconrel.2014.05.006 ↗
8. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
9. 10.7150/thno.1709810.7150/thno.17098 ↗
10. 10.1073/pnas.152208011310.1073/pnas.1522080113 ↗
11. 10.1021/nn500211210.1021/nn5002112 ↗
12. 10.1021/acsami.5b0939110.1021/acsami.5b09391 ↗
13. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
14. 10.1002/adma.20170675910.1002/adma.201706759 ↗
15. 10.1002/smll.20180410510.1002/smll.201804105 ↗
16. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
17. 10.1002/adhm.20150012910.1002/adhm.201500129 ↗
18. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
19. 10.1021/acs.nanolett.7b0526310.1021/acs.nanolett.7b05263 ↗
20. 10.1021/acsami.6b0085310.1021/acsami.6b00853 ↗
21. 10.1038/s41577-019-0127-610.1038/s41577-019-0127-6 ↗
22. 10.1016/j.ccell.2019.04.00110.1016/j.ccell.2019.04.001 ↗
23. 10.1038/nnano.2012.21210.1038/nnano.2012.212 ↗
24. 10.1007/s11060-010-0511-310.1007/s11060-010-0511-3 ↗
25. 10.1007/s10103-015-1742-510.1007/s10103-015-1742-5 ↗
26. 10.1002/jbm.a.3592710.1002/jbm.a.35927 ↗
27. 10.1080/17425247.2020.172744210.1080/17425247.2020.1727442 ↗
28. 10.1016/j.ajps.2018.09.00410.1016/j.ajps.2018.09.004 ↗
29. 10.1016/j.ijpharm.2018.07.05510.1016/j.ijpharm.2018.07.055 ↗
30. 10.7150/thno.2675810.7150/thno.26758 ↗
31. 10.1016/j.cej.2019.12317710.1016/j.cej.2019.123177 ↗
32. 10.1007/s13233-018-6139-410.1007/s13233-018-6139-4 ↗
33. 10.1080/10717544.2019.162811810.1080/10717544.2019.1628118 ↗
34. 10.1016/j.ijpharm.2019.03.04310.1016/j.ijpharm.2019.03.043 ↗
35. 10.1016/j.nano.2019.10204210.1016/j.nano.2019.102042 ↗
36. 10.1021/acsami.8b0933010.1021/acsami.8b09330 ↗
37. 10.7150/thno.4006610.7150/thno.40066 ↗
38. 10.1021/acsnano.7b0835510.1021/acsnano.7b08355 ↗
39. 10.1021/nn403202w10.1021/nn403202w ↗
40. 10.1021/acs.biomac.7b0006810.1021/acs.biomac.7b00068 ↗
41. 10.1002/wnan.151910.1002/wnan.1519 ↗
42. 10.1002/smll.20200218810.1002/smll.202002188 ↗
43. 10.1016/j.ccr.2009.10.01310.1016/j.ccr.2009.10.013 ↗
44. 10.1126/scitranslmed.300117410.1126/scitranslmed.3001174 ↗
45. 10.1126/science.118305710.1126/science.1183057 ↗
46. 10.1016/j.jconrel.2011.09.06310.1016/j.jconrel.2011.09.063 ↗
47. 10.1016/j.jconrel.2015.01.01510.1016/j.jconrel.2015.01.015 ↗
48. 10.7150/thno.719310.7150/thno.7193 ↗
49. 10.1016/S0168-3659(01)00389-310.1016/S0168-3659(01)00389-3 ↗
50. 10.1016/j.biomaterials.2007.07.02910.1016/j.biomaterials.2007.07.029 ↗
51. 10.1016/j.pisc.2016.06.04110.1016/j.pisc.2016.06.041 ↗
52. 10.1016/j.jsps.2011.12.00210.1016/j.jsps.2011.12.002 ↗
53. 10.1039/C8BM00343B10.1039/C8BM00343B ↗
54. 10.1021/ic900201p10.1021/ic900201p ↗
55. 10.1002/rcm.50910.1002/rcm.509 ↗
56. 10.1021/acs.molpharmaceut.9b0027310.1021/acs.molpharmaceut.9b00273 ↗
57. 10.1002/smll.20130117410.1002/smll.201301174 ↗
58. 10.1021/acsnano.5b0263510.1021/acsnano.5b02635 ↗
59. 10.1016/j.pdpdt.2017.04.00110.1016/j.pdpdt.2017.04.001 ↗
60. 10.1358/dof.2017.042.02.256410610.1358/dof.2017.042.02.2564106 ↗
61. 10.1155/2019/936784510.1155/2019/9367845 ↗
62. 10.1021/nn506687t10.1021/nn506687t ↗
63. 10.1158/0008-5472.CAN-06-391410.1158/0008-5472.CAN-06-3914 ↗
64. 10.1016/j.cej.2020.12445010.1016/j.cej.2020.124450 ↗
65. 10.1002/adma.20130123210.1002/adma.201301232 ↗
66. 10.1002/smll.20120078310.1002/smll.201200783 ↗
67. 10.1021/acsnano.9b0973110.1021/acsnano.9b09731 ↗
68. 10.1021/acs.molpharmaceut.8b0115710.1021/acs.molpharmaceut.8b01157 ↗
69. 10.1021/nn506963h10.1021/nn506963h ↗